VEGFA and Hypertension: Coronary artery disease, arterial hypertension, aortic stenosis, hypertrophic cardiomyopathy and obstructive sleep apnea are considered as risk factors for the development of cardiovascular adverse events during VEGF inhibitors treatment [14].